Analysts Issue Forecasts for CVRx FY2025 Earnings

CVRx, Inc. (NASDAQ:CVRX) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of CVRx in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings of ($1.58) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $14.00 target price on the stock. The consensus estimate for CVRx’s current full-year earnings is ($2.61) per share.

CVRx (NASDAQ:CVRX) last released its earnings results on Tuesday, October 29th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.12). CVRx had a negative net margin of 123.75% and a negative return on equity of 89.06%. The firm had revenue of $13.37 million during the quarter, compared to analyst estimates of $13.28 million. During the same quarter in the previous year, the firm earned ($0.43) EPS.

CVRX has been the topic of a number of other reports. Canaccord Genuity Group increased their price target on CVRx from $17.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Piper Sandler reissued an “overweight” rating and set a $16.00 target price (up from $13.00) on shares of CVRx in a research note on Wednesday, October 30th. Craig Hallum raised their price target on shares of CVRx from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, January 17th. Lake Street Capital lifted their price target on shares of CVRx from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Finally, William Blair upgraded CVRx from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 14th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, CVRx currently has an average rating of “Moderate Buy” and a consensus price target of $17.00.

CVRx Stock Down 6.5 %

Shares of NASDAQ:CVRX opened at $17.21 on Wednesday. CVRx has a 1 year low of $6.40 and a 1 year high of $29.23. The company has a debt-to-equity ratio of 0.76, a current ratio of 11.32 and a quick ratio of 10.23. The business’s 50-day moving average is $14.27 and its 200-day moving average is $11.25. The company has a market capitalization of $417.51 million, a price-to-earnings ratio of -6.37 and a beta of 1.26.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CVRX. Parkman Healthcare Partners LLC increased its position in shares of CVRx by 52.6% during the third quarter. Parkman Healthcare Partners LLC now owns 682,897 shares of the company’s stock worth $6,016,000 after acquiring an additional 235,277 shares in the last quarter. Geode Capital Management LLC lifted its position in CVRx by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 295,124 shares of the company’s stock valued at $2,600,000 after acquiring an additional 6,443 shares in the last quarter. State Street Corp lifted its position in CVRx by 11.4% in the 3rd quarter. State Street Corp now owns 264,733 shares of the company’s stock valued at $2,332,000 after acquiring an additional 27,071 shares in the last quarter. Squarepoint Ops LLC increased its holdings in CVRx by 26.3% during the 2nd quarter. Squarepoint Ops LLC now owns 91,999 shares of the company’s stock worth $1,103,000 after purchasing an additional 19,165 shares in the last quarter. Finally, PDT Partners LLC purchased a new stake in shares of CVRx in the third quarter worth approximately $543,000. Institutional investors and hedge funds own 75.27% of the company’s stock.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.